An injectable thermosensitive hydrogel self-supported by nanoparticles of PEGylated amino-modified PCL for enhanced local tumor chemotherapy.

We synthesized amino-modified poly(ε-caprolactone) PCN-b-PEG-b-PCN (PECN) triblock copolymers and studied the contribution of the introduced amino groups to the drug delivery efficiency of PECN nanoparticles (NPs) and their injectable thermosensitive hydrogels. PECN15 with an optimal amino group content was obtained. Firstly, the hydrophobic drug paclitaxel (PTX) was loaded into PECN15 up to 5.91% and formed PTX/PECN NPs 90 nm in size and with a slightly positive charge (7.3 mV). Furthermore, the injectable PTX/PECN NPs aqueous solution (25 wt%) at ambient temperature could undergo fast gelation at 37 °C and sustainedly release PTX/PECN NPs in 10 days. More importantly, compared with our previously reported PECT NPs, the PECN NPs without an increase in toxicity could improve the cell uptake and enhance intracellular drug release by responding to the acidic environment of the endosome. Thus, the PTX/PECN NPs presented a lower IC50 of 3.14 µg mL-1 than that of the PTX/PECT NPs (7.67 µg mL-1) and free PTX (4.65 µg mL-1). Moreover, through peritumoral injection, the PTX/PECNGel showed 94.27% inhibition rate of tumor growth on day 19, higher than PTX/PECTGel (72.28%) and Taxol® (47.03%). Therefore, the PECN NPs hydrogel provided a more effective injectable platform to enhance local cancer chemotherapy, and also provided the possibility of further functionalization by the reactive amino groups.

"Off/on" fluorescence imaging-guided cancer diagnosis and multi-modal therapy.

An efficient theranostic nanoplatform responding to tumour microenvironments with characters of simple and flexible combinations owns great potential in cancer diagnosis and therapy. Herein, a series of triblock copolymers, mPEG-b-PDPA-b-P(nBMA-r-cystamine) (EPB), were synthesized and among them, the structure of EPB-3 was optimized for both fluorescence imaging-guided cancer diagnosis and multi-modal therapy with good biocompatibility. (1) The self-assembled nanoparticles of EPB-3-ICG1 obtained by conjugating one ICG on EPB-3 via S-S bonds effectively performed reduction-sensitive OFF/ON fluorescence signal transition, thus inducing tumour cell-specific amplified fluorescence imaging in vitro and in vivo. (2) By entrapping Au nanorods into the co-assembled NPs of EPB-3 and EPB-3-ICG1, EPB-3-ICG1@Au NPs could synchronously induce strong tumour fluorescence imaging and high local photothermal effect, indicating the potential of imagine-guided photothermal therapy. (3) EPB-3 NPs could efficiently co-load paclitaxel (PTX) and ICG to form stable EPB-3@PTX@ICG NPs, which provided long periods of intracellular pH-sensitive sustainable drug release and highly enhanced apoptosis of 4T1 cells in vitro by the chemo-photothermal effect. Excitingly, a single intravenous injection of EPB-3@PTX@ICG NPs followed by a one-time local near-infrared light (NIR, 808 nm) irradiation treatment for 10 min could lead to significant inhibition of tumour growth, avoiding tumor metastasis and extending the survival of mice. All the above-mentioned results suggest that EPB-3 provides a nanoplatform with the characters of simple structure, convenience of use and flexible combination, holding potential for multi-modal diagnosis and therapy.

Delivery of Liposomes with Different Sizes to Mice Brain after Sonication by Focused Ultrasound in the Presence of Microbubbles.

Imaging or therapeutic agents larger than the blood-brain barrier's (BBB) exclusion threshold of 400 Da could be delivered locally, non-invasively and reversibly by focused ultrasound (FUS) with circulating microbubbles. The size of agents is an important factor to the delivery outcome using this method. Liposomes are important drug carriers with controllable sizes in a range of nanometers. However, discrepancies among deliveries of intact liposomes with different sizes, especially those larger than 50 nm, across the BBB opened by FUS with microbubbles remain unexplored. In the present study, rhodamine-labeled long-circulating pegylated liposomes with diameters of 55 nm, 120 nm and 200 nm were delivered to mice brains after BBB disruption by pulsed FUS with microbubbles. Four groups of peak rarefactional pressure and microbubble dosages were used: 0.53 MPa with 0.1 µL/g (group 1), 0.53 MPa with 0.5 µL/g (group 2), 0.64 MPa with 0.1 µL/g (group 3) and 0.64 MPa with 0.5 µL/g (group 4). The delivery outcome was observed using fluorescence imaging of brain sections. It was found that the delivery of 55-nm liposomes showed higher success rates than 120-nm or 200-nm liposomes from groups 1-3. The result indicated that it may be more difficult to deliver larger liposomes (>120 nm) passively than 55-nm liposomes after BBB opening by FUS with microbubbles. The relative fluorescence area of 55-nm liposomes to the total area of the sonicated region was statistically larger than that of the 120-nm or 200-nm liposomes. Increasing peak rarefactional pressure amplitude or microbubble dose could induce more accumulation of liposomes in the brain using FUS with microbubbles. Moreover, the distribution pattern of delivered liposomes was heterogeneous and characterized by separated fluorescence spots with cloud-like periphery surrounding a bright center, indicating confined diffusion in the extracellular matrix after extravasation from the microvasculature. These findings are expected to provide useful information for developing FUS with microbubbles as an effective trans-BBB liposomal drug delivery strategy.